Drug maker Adcock Ingram has reported a double-digit increase in full-year earnings and dividends even as the seller of brands such as Corenza C and Panado navigated a weak economy that saw consumers coming under increasing pressure.
It described its results as a"healthy financial and operational performance" amid a weak economy characterised by currency weakness and volatility. It also noted that SA's cash-strapped consumers had also been constrained during the period.
Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más: